Compare EHang Holdings Ltd - ADR (EH) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Enveric Biosciences Inc — how do they compare? EHang Holdings Ltd - ADR trades at $4.09 (market cap $314.00M), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: EHang Holdings Ltd - ADR is far larger — about 46.9× Enveric Biosciences Inc's market cap, and EHang Holdings Ltd - ADR is more actively traded (856,650 versus 41,141). Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Enveric Biosciences Inc for 14 Days on average.
| EH | ENVB | |
|---|---|---|
Market Cap | $314.00M | $6.69M |
Volume | 856,650 | 41,141 |
Sector | Industrials | Health |
52-Week High | $18.94 | $10.80 |
52-Week Low | $4.03 | $1.27 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | $265.69M | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.14, up 0.98% on the day, amid a bearish technical outlook and mixed financials. Revenue declined to $418M in 2025 with a net loss of $276M, though gross margins remain strong at 61.5%. Recent news includes expansion of its Global Fast Track Program to Vietnam but also multiple law firm investigations into investor claims, creating a cautious sentiment.
The outlook is challenged by persistent losses and regulatory scrutiny, but the company's cash position of $1.12B provides some buffer. Investment opportunities lie in the nascent eVTOL market, while risks include execution missteps and intense competition. Analyst consensus is divided, reflecting high uncertainty.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
